首页|Dual-targeted halofuginone hydrobromide nanocomplexes for promotion of macrophage repolarization and apoptosis of rheumatoid arthritis fibroblast-like synoviocytes in adjuvant-induced arthritis in rats

Dual-targeted halofuginone hydrobromide nanocomplexes for promotion of macrophage repolarization and apoptosis of rheumatoid arthritis fibroblast-like synoviocytes in adjuvant-induced arthritis in rats

扫码查看
原文链接
  • 万方数据
  • 维普
Rheumatoid arthritis(RA)is a prevalent autoimmune disease characterized by chronic inflammation and excessive proliferation of the synovium.Currently,treatment options focus on either reducing inflam-mation or inhibiting synovial hyperplasia.However,these modalities are unsatisfactory in achieving the desired therapeutic outcomes.Halofuginone hydrobromide(HF),an herbal active ingredient,has demonstrated pharmacological effects of both anti-inflammation and inhibition of synovial hyperplasia proliferation.However,HF's medical efficacy is limited due to its poor water solubility,short half-life(ti/2),and non-target toxicity.In the current study,by using the advantages of nanotechnology,we presented a novel dual-targeted nanocomplex,termed HA-M@P@HF NPs,which consisted of a hyaluronic acid(HA)-modified hybrid membrane(M)-camouflaged poly lactic-co-glycolic acid(PLGA)nanosystem for HF delivery.These nanocomplexes not only overcame the limitations of HF but also achieved simultaneous targeting of inflammatory macrophages and human fibroblast-like synoviocytes-RA(HFLS-RA).In vivo experiments demonstrated that these nanocomplexes effectively suppressed immune-mediated inflam-mation and synovial hyperplasia,safeguarding against bone destruction in rats with adjuvant-induced arthritis(AIA).Remarkable anti-arthritic effects of these nanocomplexes were accomplished through promoting repolarization of M1-to-M2 macrophages and apoptosis of HFLS-RA,thereby offering a promising therapeutic strategy for RA.

Halofuginone hydrobromideRheumatoid arthritisNanocomplexesMacrophage polarizationRheumatoid arthritis fibroblast-likesynoviocytesAdjuvant-induced arthritis

Junping Zhu、Ye Lin、Gejing Li、Yini He、Zhaoli Su、Yuanyuan Tang、Ye Zhang、Qian Xu、Zhongliu Yao、Hua Zhou、Bin Liu、Xiong Cai

展开 >

Institute of Innovation and Applied Research in Chinese Medicine

Department of Rheumatology of First Hospital,Hunan University of Chinese Medicine,Changsha,410208,China

College of Biology,Hunan University,Changsha,410082,China

State Key Laboratory of Traditional Chinese Medicine Syndrome,Guangdong Provincial Hospital of Chinese Medicine,Guangdong Provincial Academy of Chinese Medical Sciences,The Second Affiliated Hospital of Guangzhou University of Chinese Medicine,Guangzhou,510006,China

展开 >

2024

10.1016/j.jpha.2024.100981

药物分析学报(英文)
西安交通大学

药物分析学报(英文)

影响因子：0.244
ISSN：2095-1779
年,卷(期)：2024.14(11)